Preview Newsletter
fosamax june 29
-
Washington Litigation Departments of the Year: Products Liability, Skadden, Arps, Slate, Meagher & Flom
Jun 29, 2015 | The National Law Journal
By Amanda Bronstad
After a judge tossed out a bellwether case in 2013, lawyers at Skadden, Arps, Slate, Meagher & Flom moved for the dismissal of 650 additional lawsuits that linked osteoporosis drug Fosamax to femoral fractures. The firm found a hole in case law shielding plaintiffs from federal pre-emption... -
Osteoporosis Drugs Market Expected to Reach USD 8.9 Billion Globally in 2020
Jun 26, 2015 | Medgadget
... However, during the forecast period the class is expected to report a negative CAGR due to expiry of drugs (Reclast and Boniva) and frequent evidences of chronic side-effects. In addition, owing to year on year decline in the sales of Fosamax, highest revenue generating drug of this class is also expected to pull back the growth of this market...
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Full Text of Stories Below
-
Jun 29, 2015 | The National Law Journal
By Amanda Bronstad
After a judge tossed out a bellwether case in 2013, lawyers at Skadden, Arps, Slate, Meagher & Flom moved for the dismissal of 650 additional lawsuits that linked osteoporosis drug Fosamax to femoral fractures.
The firm found a hole in case law shielding plaintiffs from federal pre-emption. The U.S. Supreme Court's 2009 decision in Wyeth v. Levine, partner Jessica Miller said, "closed the door on pre-emption and left a sliver open — like a quarter of a centimeter open. And that quarter of a centimeter is what applies in this case."
On March 26, 2014, a federal judge in New Jersey agreed, finding that Skadden's client, Merck & Co. Inc., could not have warned of the osteoporosis drug's risks any earlier than it had because the U.S. Food and Drug Administration had rejected its proposed stronger warning label. The cases had been filed by plaintiffs who took the drug before Merck changed the labels.
Skadden went on to win a June 17, 2014, ruling on summary judgment in the first bellwether case filed by someone who took the drug following the label change. The firm's lawyers have a pending motion to dismiss another 250 cases based on that decision, said John Beisner, leader of the mass torts, insurance and consumer-litigation group.
Merck legal director March Coleman in an email described Miller and Beisner as "key players on Merck's legal team" and "heavily involved in crafting the legal strategy and pre-emption briefing."
When it comes to mass torts, Skadden often takes the lead on key points. Beisner and Miller knocked out a novel argument in another case that would have allowed lawsuits to be filed in New York seeking medical monitoring costs. Such claims seek preventative costs for individuals exposed to a dangerous product. They are allowed in some states, but most prohibit them.
"The trouble that courts have with that is, of course, you're not injured," Beisner said...
For full story:
http://www.nationallawjournal.com/home/id=1202730667623/Skadden-Arps-Slate-Meagher--Flom?mcode=1202615432992&curindex=1&slreturn=20150529044125
-
Osteoporosis Drugs Market Expected to Reach USD 8.9 Billion Globally in 2020
Jun 26, 2015 | Medgadget
According to a new market report published by U.S. based market research company, Transparency Market Research “Osteoporosis Drugs Market – Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends & Forecast, 2014 – 2020” the global osteoporosis drugs market was valued at USD 8.4 billion in 2013 and is estimated to reach a market worth of USD 8.9 billion in 2020 growing at a CAGR of 1.2% from 2014 to 2020.
Browse the full Osteoporosis Drugs Market Report at http://www.transparencymarketresearch.com/osteoporosis-drug-market.html Steadily rising prevalence of osteoporosis is an important healthcare issue on a worldwide level. Osteoporosis is a bone disorder, in which, the bone mass and bone density are depleted leading to alteration in bone microstructure.
...Osteoporosis drugs market is segmented on the basis of drug classes used to treat the disease. Amongst all the drug classes the global osteoporosis drugs market is dominated by bisphosphonates segment accounting for a market share of 48.2% in 2013. However, during the forecast period the class is expected to report a negative CAGR due to expiry of drugs (Reclast and Boniva) and frequent evidences of chronic side-effects. In addition, owing to year on year decline in the sales of Fosamax, highest revenue generating drug of this class is also expected to pull back the growth of this market. On the contrary, the class is expected to retain its dominant position in the market in terms of revenue due to first mover advantage and extensive prescriptions of bisphosphonates in osteoporosis treatment. Similarly, SERM drug class which occupied second largest share of the market in 2013 is expected to heavily decline its market share due to patent expiry of its blockbuster drug Evista in 2014. However, demand for calcium and vitamin D will remain high during the forecast period. This is because; calcium and vitamin D supplements are used as first line as well as prolonged term treatment with osteoporosis. Although available as over-the-counter (OTC) drugs, the sales revenue generated by these drugs is considerably high and is estimated to increase during the forecast period.
Currently, certain novel compounds for the treatment of osteoporosis are under investigation in both preclinical and clinical settings. Some of the major candidates such as Odanacatib, Romosozumab and others are currently in phase III clinical trials. These drugs promise fewer side effects as compared to the currently available drugs and provide improved efficacy. Hence, expected launch of these drugs during the forecast period is anticipated to have significant impact on the growth of the overall osteoporosis drugs market...
For full story:
http://www.medgadget.com/2015/06/osteoporosis-drugs-market-expected-to-reach-usd-8-9-billion-globally-in-2020.html
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Full Text of Stories Below
Add recipients
Suggested